Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
AMSTERDAM, the Netherlands, Dec. 14, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology Index® (NBI) as part of NBI's annual selection of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market® that meet NBI's eligibility criteria. uniQure will be added to the NBI effective prior to market open on December 21, 2015.
The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark and is re-ranked annually in December. Additional information on the eligibility criteria and further details about the index are available here: https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Aicha Diba
Investor Relations
Direct : +31 20 240 6100
Main: +31 20 566 7394
[email protected]
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]
